Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with ...
Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...
Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...
(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results